步入利民股份的智能制造车间，现代化生产的图景扑面而来：智能立体仓库中，货位指示灯有序闪烁， 出库物料自动输送至待运区；MES管控平台的大屏上，生产进度、设备负载等数据实时跳动，精准呈 现每一道工序的运行状态。这里生产的农药制剂，凭借其低毒、环保的特性，已成为备受信赖的"绿色 利器"。如今，这些产品正从利民股份的生产线出发，走向全球130多个国家和地区，成为中国农药工业 高质量出海的一张亮眼名片。 近日，利民股份副董事长张庆在接受上海证券报记者专访时表示："'十五五'期间，我们将持续聚焦合 成生物领域，以绿色化制造、AI驱动研发、全球化布局为抓手，加快形成农业新质生产力。" 合成生物农药抢占先机 随着我国新一轮千亿斤粮食产能提升行动的扎实推进，农药行业在保障国家粮食安全中的战略地位愈发 凸显。 面对机遇，利民股份的底气源于深厚的产业根基：公司已形成覆盖农兽药原药与制剂、新能源材料的全 产业链布局。在代森锰锌、三乙膦酸铝、草铵膦、阿维菌素和甲维盐等核心产品领域，其产能均位居国 内前列。依托完善的产品体系，利民的产品能够广泛适用于大田作物与经济作物，精准响应多样化的病 虫害防控需求。 当前，中国农药行业正处于转型升 ...

证券日报网讯12月29日，海利尔（603639）在互动平台回答投资者提问时表示，公司有甲维盐产能，具 体情况请查阅公司定期报告。 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Insights - The company achieved significant year-on-year growth in performance, with revenue of 3.6 billion yuan in the first three quarters of 2025, up 7.6% year-on-year, and a net profit attributable to shareholders of 390 million yuan, up 661.7% year-on-year [4][12] - The growth is attributed to increased sales and prices of key products, improved gross margins, and increased investment income from affiliated companies [13] - The company is strategically positioning itself in AI and synthetic biology, with plans for the first fluorinated insecticide to be mass-produced in 2025 and collaborations to enhance pesticide development efficiency [14][15] Financial Performance Summary - For the first three quarters of 2025, the company reported revenue of 3.6 billion yuan, a net profit of 390 million yuan, and a non-recurring net profit of 380 million yuan, showing substantial increases of 7.6%, 661.7%, and 1014.9% respectively [4][12] - In Q3 2025, revenue was 1.15 billion yuan, up 9.7% year-on-year but down 7.6% quarter-on-quarter, with a net profit of 120 million yuan, reflecting a year-on-year increase of 522.3% but a quarter-on-quarter decrease of 24.6% [12][13] - The company expects revenue growth of 21%, 9%, and 8% for 2025, 2026, and 2027 respectively, with net profit growth of 528%, 12%, and 12% for the same years [15][16] Market Position and Strategy - The company is focusing on synthetic biology and AI applications to enhance its product development capabilities, which is expected to open new growth avenues [14][15] - The strategic partnership with Green Xin Nuo Bio aims to develop peptide-based biopesticides, indicating a move towards industrialization of synthetic biology strategies [14] - The company has also adjusted prices for key products in response to raw material cost increases and market demand, indicating proactive market strategies [13]

Core Viewpoint - The company, Limin Co., Ltd. (002734.SZ), has reported a significant increase in profitability for the first three quarters of 2025, with a projected net profit of 384 to 394 million yuan, representing a year-on-year growth of 649.71% to 669.25% due to rising sales volumes and prices of its main products, improved gross margins, and increased investment income from affiliated companies [1][2]. Financial Performance - For Q3 2025, the company expects a net profit of 115 to 125 million yuan, reflecting a year-on-year increase of 490.85% to 542.23%, with a non-recurring net profit growth of 1993.39% to 2192.79% [2]. - In the first half of 2025, the company's product sales gross margin was 26.13%, an increase of 8.11% year-on-year, while accounts receivable decreased by 8.01% to 599 million yuan, and the debt-to-asset ratio was 47.78%, down 11.75% year-on-year [3]. Product Performance - The company's agricultural fungicides and insecticides showed steady growth, with fungicide revenue at 1.24 billion yuan and a gross margin of 33.77%, up 7.70% year-on-year; insecticide revenue was 748 million yuan with a gross margin of 24.32%, up 11.72% year-on-year. However, herbicides underperformed, generating 208 million yuan in revenue with a gross margin decrease of 7.47% [4]. Market Expansion - Limin Co., Ltd. is actively pursuing international expansion, with a focus on strategic markets in Africa, Southeast Asia, and Latin America. In the first half of 2025, overseas revenue reached 848 million yuan, a 22.42% increase year-on-year, accounting for 34.57% of total revenue [5][6]. - The company has made significant progress in Brazil, obtaining multiple registrations for its products, including the key fungicide, Mancozeb, which is crucial for its growth in the Brazilian market [6][7]. Industry Trends - The company is positioned to benefit from the increasing demand for its products, particularly in Brazil, where the market for Mancozeb is expected to grow due to rising soybean planting areas. The company has signed a registration agreement for Mancozeb in Brazil, which is the largest market for this product globally [7].

Investment Rating - The report maintains an "Outperform the Market" rating for the company [5][18]. Core Views - The company is expected to achieve significant year-on-year growth in net profit for the first three quarters of 2025, with estimates ranging from 384 million to 394 million yuan, representing a growth of 649.71% to 669.25% [1][8]. - The increase in profit is attributed to rising sales and prices of key products, improved gross margins, and increased investment income from affiliated companies [1][8]. - The company has signed a registration agreement for the sale of its product in Brazil, which is the largest market for the product globally, indicating strong future sales potential [2][13]. Summary by Sections Financial Performance - The company forecasts a net profit of 529 million yuan for 2025, with a projected earnings per share (EPS) of 1.26 yuan, corresponding to a price-to-earnings (PE) ratio of 15.4 [4][18]. - Revenue is expected to grow from 4.24 billion yuan in 2023 to 4.96 billion yuan in 2025, reflecting a growth rate of 17% [4][22]. Product Pricing and Market Trends - Key products such as甲维盐 and 阿维菌素 have seen price increases, with甲维盐 rising from 500,000 yuan/ton to 650,000 yuan/ton and 阿维菌素 from 350,000 yuan/ton to 455,000 yuan/ton since March 2024 [2][14]. - The price of代森锰锌 has increased from 23,500 yuan/ton to 27,500 yuan/ton since March 2025, contributing to improved profitability [2][13]. New Business Developments - The company has accelerated its new business layout by acquiring a 51% stake in 德彦智创, which focuses on global pesticide creation using AI technology [3][17]. - Strategic partnerships with various technology companies aim to develop innovative agricultural products, potentially leading to high-barrier new products and growth opportunities [3][17].

Industry Research Summary - Pesticide Industry Industry Overview - The global pesticide market is approximately $70 billion, highly concentrated with multinational companies such as Syngenta, FMC, Bayer, Corteva, and BASF dominating the market, providing integrated services of seeds, fertilizers, and pesticides [1][2] - The domestic pesticide market in China is fragmented, influenced by historical factors and the participation of both domestic and foreign enterprises. About 70% of raw material exports are for international markets, while 30% are for domestic sales [1][4] Market Dynamics - In 2021, a significant increase in demand occurred due to inventory replenishment, but prices began to decline from Q4 2022, leading to a bottoming out phase in 2024 and 2025 [1][5] - Key products expected to perform well in 2025 include Bacillus subtilis, Mancozeb, Abamectin, Methomyl, and Acetochlor, driven by factors such as disease outbreaks and supply shortages [1][6] Supply and Demand Analysis - Glyphosate has a global supply of approximately 1.2 million tons, with China supplying 800,000 tons and Monsanto accounting for 370,000-380,000 tons. The global demand is around 900,000 tons, with a capacity utilization rate of about 75% [1][9] - The price of glyphosate has increased from 23,000 yuan to 27,000 yuan per ton due to reduced supply and declining inventory, leading to improved profitability for companies [1][9] Product-Specific Insights - Glyphosate's future outlook is optimistic due to stable supply-demand dynamics and no new capacity additions allowed by policy [1][8] - In contrast, Glufosinate has faced oversupply issues since being listed in a restricted directory in 2024, with demand growth lagging behind supply growth, resulting in poor price and margin performance [1][10][11] Company-Specific Strategies - Yangnong Chemical's investment logic is based on capacity expansion and price elasticity opportunities, while Limin Co. focuses on reversing its main business challenges and developing innovative products [1][13] - Guangxin's core competitiveness lies in its comprehensive layout along the phosgene industrial chain, enabling it to achieve the lowest cost operations [1][15] - Runfeng Company emphasizes global formulation channel development, achieving periodic growth through continuous registration and channel establishment [1][16] Key Considerations for Industry Analysis - Important factors to monitor include cyclical trends, supply-demand relationships, the development of innovative products, and the characteristics of the formulation industry, which is asset-light and high-turnover [1][17] - Tracking inventory can be done through multinational company financial reports, communication with listed companies, and industry exhibitions [1][12]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 20.90 CNY based on a projected EPS of 0.95, 1.35, and 1.79 CNY for 2025-2027 [4][7]. Core Views - The company experienced a year-on-year revenue growth of 6.84% in Q2, driven by a 9.20% increase in pesticide sales, despite a 1.26% decline in average product prices [10]. - The company's gross profit margin for Q2 was 23.79%, remaining stable year-on-year, while net profit increased by 35.24% to 0.97 billion CNY due to reduced asset impairment losses [10]. - The Hengning base is expected to continue reducing losses as its operational efficiency improves, potentially contributing positively in the future [10]. Financial Summary - Revenue for 2023 is projected at 4,398 million CNY, with a decline of 3.0% year-on-year, followed by a forecasted increase of 23.6% in 2025 [6]. - Operating profit is expected to drop to 242 million CNY in 2024, a decrease of 57.5%, before recovering to 378 million CNY in 2025 [6]. - The net profit attributable to the parent company is forecasted to be 473 million CNY in 2023, with a significant drop of 61.7% in 2024, followed by a recovery to 324 million CNY in 2025 [6]. - The company’s gross margin is expected to decline to 23.9% in 2024, before gradually improving to 25.7% by 2027 [6].

Core Viewpoint - The company's second-quarter performance showed a year-on-year increase driven by sales growth and a reduction in impairment losses, despite a generally low industry sentiment and price pressures on key products [1][2]. Group 1: Sales and Financial Performance - The company's pesticide business saw a 9.20% year-on-year increase in sales volume in the second quarter, leading to a revenue of 1.345 billion, which is a 6.84% increase year-on-year [1]. - The average price of the company's pesticide products decreased by 1.26% year-on-year in the second quarter, indicating stabilization after a period of decline [1]. - The net profit attributable to the parent company reached 97 million in the second quarter, reflecting a year-on-year growth of 35.24%, primarily due to reduced asset impairment losses [1]. Group 2: Operational Developments - The Hengning subsidiary, a key growth driver for the company, has seen an increase in operational efficiency, with total assets reaching nearly 2 billion [1]. - The Hengning project has faced challenges since its initial production in June 2022, resulting in losses of 141 million and 163 million for 2023 and 2024, respectively, attributed to high initial investment and low utilization rates [2]. - Improvements in the Hengning project are expected as production capacity utilization increases, leading to a reduction in losses and potential positive contributions in the future [2]. Group 3: Profit Forecast and Investment Recommendations - Due to the declining prices of key products in the pesticide industry, the company's earnings per share (EPS) forecasts for 2025-2027 have been adjusted to 0.95, 1.35, and 1.79, down from previous estimates [3]. - The target price is set at 20.90, based on a 22 times price-to-earnings ratio for comparable companies, while maintaining a buy rating [3].

Core Viewpoint - The announcement provides an overview of the operational performance of Shaanxi Meibang Pharmaceutical Group Co., Ltd. for the first half of 2025, detailing production, sales, and revenue figures for its main products, as well as price changes for both products and raw materials [1]. Group 1: Main Products Performance - The production volume for fungicides was 3,033.70 tons, with sales of 3,188.00 tons, generating revenue of 252.60 million yuan [1]. - The production volume for insecticides was 1,677.17 tons, with sales of 2,029.64 tons, generating revenue of 161.27 million yuan [1]. - Other products had a production volume of 1,282.02 tons, with sales of 1,214.48 tons, generating revenue of 68.80 million yuan [1]. Group 2: Price Changes of Main Products - The average selling price of fungicides decreased from 87,652.39 yuan/ton to 79,235.29 yuan/ton, a change of -9.60% [1]. - The average selling price of insecticides decreased from 83,721.80 yuan/ton to 79,455.81 yuan/ton, a change of -5.10% [1]. - The average selling price of other products remained relatively stable, changing from 56,649.18 yuan/ton to 56,653.30 yuan/ton, a change of 0.01% [1]. Group 3: Price Changes of Raw Materials - The price of benzimidazole decreased from 8.91 million yuan/ton to 8.47 million yuan/ton, a change of -4.98% [1]. - The price of pyrazole decreased from 15.19 million yuan/ton to 14.22 million yuan/ton, a change of -6.36% [1]. - The price of flubendiamide decreased significantly from 30.02 million yuan/ton to 24.65 million yuan/ton, a change of -17.89% [1]. - The price of methomyl increased from 46.33 million yuan/ton to 62.47 million yuan/ton, a change of 34.84% [1]. - The price of methyl thiophanate decreased from 3.39 million yuan/ton to 2.98 million yuan/ton, a change of -12.16% [1].

Financial Performance - In the first half of 2025, the company achieved a sales revenue of CNY 2.452 billion, a year-on-year increase of 6.69% [3] - Net profit reached CNY 269 million, reflecting a significant year-on-year growth of 747.13% [3] - The gross profit margin was 26.13%, up by 8.11% compared to the previous year [3] - Accounts receivable decreased by 8.01% to CNY 599 million [3] - The debt-to-asset ratio improved to 47.78%, down by 11.75% year-on-year [3] Key Drivers of Performance - Core products saw both volume and price increases, with strong market demand for key products such as Mancozeb, Chlorothalonil, Abamectin, and Methomyl [3] - The "Safety Cushion Resilience Plan" effectively controlled costs and improved efficiency through optimized production processes and supply chain management [4] - Successful expansion into overseas markets, particularly in Brazil, where the company obtained several product registrations [4] - Enhanced capacity utilization and operational efficiency due to improved market conditions and internal management [4] Product Contribution - The agricultural pesticide segment generated CNY 2.199 billion in revenue, a 4.63% increase year-on-year, with a gross margin of 26.45% [6] - The veterinary medicine segment reported revenue of CNY 229 million, a growth of 27.73% year-on-year, with a gross margin of 21.66% [6] - Specific product performance included: - Agricultural fungicides: CNY 1.240 billion in revenue, gross margin of 33.77% [6] - Agricultural insecticides: CNY 748 million in revenue, gross margin of 24.32% [6] - Agricultural herbicides: CNY 208 million in revenue, with a decrease in gross margin by 7.47% [6] Investment and Market Outlook - Investment income increased significantly, primarily from the investment in Jiangsu Xinhai Agricultural Chemical Co., Ltd. [7] - The price of Mancozeb has risen approximately 20% since January 2025, with strong demand in Brazil, where the product is crucial for soybean disease management [8] - The company expects continued growth in demand for Mancozeb, with import volumes in Brazil nearly doubling in 2024 to 88,000 tons [8] Strategic Initiatives - The company is focusing on enhancing brand influence and expanding overseas operations, with significant revenue from Brazil (CNY 200 million) and the U.S. (over CNY 70 million) in the first half of 2025 [11] - The implementation of the "One Certificate, One Product" policy is anticipated to benefit the company due to its extensive registration resources [12] - Future plans include improving production quality, expanding market presence, and enhancing technological innovation [18]